Future prospects of systemic host modulatory agents in periodontal therapy

British Dental Journal

Volumn 214, Issue 9, 2013, Pages 467-471

  Gokhale, S R ^a   Padhye, A M ^b  

^a MA Rangoonwala College of Dental Sciences and Research Center   (India)

^b GOVERNMENT DENTAL COLLEGE AND HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; IMMUNOLOGIC FACTOR;

ARTICLE; DISEASE COURSE; DRUG ANTAGONISM; DRUG EFFECT; FORECASTING; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOLOGY; IMMUNOMODULATION; MICROBIOLOGY; PERIODONTITIS; SIGNAL TRANSDUCTION; WOUND HEALING;

CYTOKINES; DISEASE PROGRESSION; FORECASTING; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; PERIODONTITIS; SIGNAL TRANSDUCTION; WOUND HEALING;

EID: 84877777006     PISSN: 00070610     EISSN: 17417503     Source Type: Journal    
DOI: 10.1038/sj.bdj.2013.432     Document Type: Article

References (36)

1. Page R. The role of inflammatory mediators in the pathogenesis of periodontal disease. J Periodont Res 1991; 26: 230-242.
2. Kantarci A, Hasturk H, Van Dyke T E. Host-mediated resolution of inflammation in periodontal diseases. Periodontol 2000 2006; 40: 144-163.
3. Preshaw P. Host response modulation in periodontics. Periodontol 2000 2008; 48: 92-110.
4. Oringer R J, Research, Science, and Therapy Committee of the American Academy of Periodontology. Modulation of the host response in periodontal therapy. J Periodontol 2002; 73: 460-470.
5. Salvi G E, Lang N P. Host response modulation in the management of periodontal diseases. J Clin Peridontol 2005; 32(Suppl 6): 108-129.
6. Kirkwood K L, Cirelli J A, Rogers J E, Giannobile W V. Novel host response therapeutic approaches to treat periodontal diseases. Periodontol 2000 2007; 43: 294-315.
7. Kirkwood K L, Li F, Rogers J E et al. A p38 alpha selective mitogen activated protein kinase inhibitor prevents periodontal bone loss. J Pharmacol Exp Ther 2007; 320: 56-63.
8. Boissy P, Andersen T L, Lund T, Kupisiewicz K, Plesner T, Delaissé J M. Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions. Leuk Res 2008; 32: 1661-1668.
9. Hongming H, Jian H. Bortezomib inhibits maturation and function of osteoclasts from PBMCs of patients with multiple myeloma by downregulating TRAF6. Leuk Res 2009; 33: 115-122.
10. McIntyre K W, Shuster D J, Gillooly K M et al. A highly selective inhibitor of I kappa B kinase, BMS 345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice. Arthritis Rheum 2003; 48: 2652-2659.
11. Souza J A C, Rossa C Jr, Garlet G P, Nogueira A V, Cirelli J A. Modulation of host cell signalling pathways as a therapeutic approach in periodontal disease. J Appl Oral Sci 2012; 20: 128-138.
12. Garcia de Aquino S, Manzolli Leite F R, Stach-Machado D R, Francisco da Silva J A, Spolidorio L C, Rossa C Jr. Signalling pathways associated with the expression of inflammatory mediators activated during the course of two models of experimental periodontitis. Life Sci 2009; 84: 745-754.
13. Parganas E, Wang D, Stravopodis D et al. Jak2 is essential for signalling through a variety of cytokine receptors. Cell 1998; 93: 385-395.
14. West K. CP 690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders. Curr Opin Investig Drugs 2009; 10: 491-504.
15. Elliott M J, Feldmann M, Maini R N. TNF a blockade in rheumatoid arthritis: rationale, clinical outcomes and mechanisms of action. Int J Immunopharmacol 1995; 17: 141-145.
16. Wooley P H, Dutcher J, Widmer M B, Gillis S. Influence of a recombinant human soluble tumour necrosis factor receptor FC fusion protein on type II collagen induced arthritis in mice. J Immunol 1993; 151: 6602-6607.
17. Waykole Y P, Doiphode S S, Rakhewar P S, Mhaske M. Anticytokine therapy for periodontal diseases: where are we now? J Indian Soc Periodontol 2009; 13: 64-68.
18. Pers J O, Saraux A, Pierre R, Youinou P. Anti TNF alpha immunotherapy is associated with increased gingival inflammation without clinical attachment loss in subjects with rheumatoid arthritis. J Periodontol 2008; 79: 1645-1651.
19. Di Paola R, Mazzon E, Muià C et al. Effects of Etanercept, a tumour necrosis factor-alpha antagonist, in an experimental model of periodontitis in rats. Br J Pharmacol 2007; 150: 286-297.
20. Trepicchio W L, Bozza M, Pedneault G, Dorner A J. Recombinant human IL 11 attenuates the inflammatory response through downregulation of proinflammatory cytokine release and nitric oxide production. J Immunol 1996; 157: 3627-3634.
21. Leng S X, Elias J A. Interleukin 11 inhibits macrophage IL 12 production. J Immunol 1997; 159: 2161-2168.
22. Martuscelli G, Fiorellini J P, Crohin C C, Howell T H. The effect of IL 11 on the progression of ligature induced periodontal disease in the beagle dog. J Periodontal 2000; 71: 573-578.
23. Han J Y, Reynolds M A. Effect of anti-rheumatic agents on periodontal parameters and biomarkers of inflammation: a systematic review and meta-analysis. J Periodontal Implant Sci 2012; 42: 3-12.
24. Van der meer J W, Popa C, Netea M G. Side effects of anti-cytokine strategies. Neth J Med 2005; 63: 78-80.
25. Delgado M, Pozo D, Ganea D. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev 2004; 56: 249-290.
26. Linden G J, Mullally B H, Burden D J et al. Changes in vasoactive intestinal peptide in gingival crevicular fluid in response to periodontal treatment. J Clin Periodontol 2002; 29: 484-489.
27. Foster N, Cheetham J, Taylor J J, Preshaw P M. VIP Inhibits Porphyromonas gingivalis LPS-induced immune responses in human monocytes. J Dent Res 2005; 84: 999-1004.
28. Foster N, Lea S R, Preshaw P M, Taylor J J. Pivotal advance: vasoactive intestinal peptide inhibits upregulation of human monocyte TLR2 and TLR4 by LPS and differentiation of monocytes to macrophages. J Leukoc Biol 2007; 81: 893-903.
29. Gürkan A, Emingil G, Nizam N et al. Therapeutic efficacy of vasoactive intestinal peptide in escherichia coli lipopolysaccharide-induced experimental periodontitis in rats. J Periodontol 2009; 80: 1655-1664.
30. Lohinai Z, Stachlewitz R, Virag L, Szekely A D, Hasko G, Szabo C. Evidence for reactive nitrogen species formation in the gingivomucosal tissue. J Dent Res 2001; 80: 470-475.
31. Lohinai Z, Mabley J G, Feher E, Marton A, Komjati K, Szabo C. Role of the activation of the nuclear enzyme poly( ADP ribose) polymerase in the pathogenesis of periodontitis. J Dent Res 2003; 82: 987-992.
32. Leitao R F, Ribeiro R A, Chaves H V, Rocha F A, Lima V, Brito G A. Nitric oxide synthase inhibition prevents alveolar bone resorption in experimental periodontitis in rats. J Periodontol 2005; 76: 956-963.
33. Menezes A M, De Souza G F, Gomes A S et al. S Nitrosoglutathione decreases inflammation and bone resorption in experimental periodontitis in rats. J Periodontol 2012; 83: 514-521.
34. Kumar A J, Anumala N, Avula H. Novel and often bizarre strategies in the treatment of periodontal disease. J Indian Soc Periodontol 2012; 16: 4-10.
35. Neville-Webbe H L, Coleman R E. Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease. Eur J Cancer 2010; 46: 1211-1222.
36. El-Sharkawy H, Elewa M, Elmeadawy S. Does Denosumab affect periodontal bone loss in postmenopausal women? (A randomized placebo-controlled trial). Egypt Dent J 2012; 58: 1321-1325.